$SXTP

60 DEGREES PHARMACEUTICALS, INC. (SXTP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001946563 DC 0001946563 2026-08-05 2026-08-05 0001946563 SXTP:CommonStockParValue0.0001PerShareMember 2026-08-05 2026-08-05 0001946563 SXTP:WarrantsEachWarrantToPurchaseOneShareOfCommonStockMember 2026-08-05 2026-08-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNIT

60 DEGREES PHARMACEUTICALS, INC. (SXTP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ea030026001ex10-1.htm FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “ Agreement ”) is made and entered into effective as of July [___], 2026, between 60 DEGREES PHARMACEUTICALS, INC., a Delaware

60 Degrees Pharmaceuticals (SXTP) said it agreed to a Nasdaq-priced at-the-market private placement. It will sell 574,713 shares (or pre-funded warrants) at $1.74 per share, with Series A warrants and Series B warrants exercisable at $1.49. Gross proceeds are about $1.0 million. Net proceeds will fund working capital. Closing expected around July 31, 2026.

60 Degrees Pharmaceuticals (SXTP) said it signed an exclusive option agreement with Florida State University Research Foundation covering IP for Castanospermine to target multiple tick-borne diseases, including Powassan virus, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease. The option allows SXTP to negotiate an exclusive U.S. license. The company cited preclinical antiviral and immunomodulatory activity and prior human safety experience from Celgosivir.

60 Degrees Pharmaceuticals (NASDAQ: SXTP; SXTPW) said it signed an exclusive option agreement with Florida State University Research Foundation to negotiate an exclusive U.S. license for castanospermine IP. The compound would be evaluated for Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease, with an evaluation period to plan commercialization.

DOW GEOFFREY S (President and CEO) purchased 7,350 shares of 60 DEGREES PHARMACEUTICALS, INC. (SXTP) at $1.38 on 2026-06-12.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) has appointed Eric Francois to its board of directors. Mr. Francois brings over 20 years of leadership experience in healthcare and life sciences, previously holding roles at Raymond James, Credit Suisse, SCYNEXIS, Inc., and CERo Therapeutics Holdings. The appointment comes as the company's shares have significantly declined, despite recent revenue growth, and amid other company developments such as positive results from a babesiosis treatment trial, new telehealth availability for ARAKODA, and regulatory updates.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) has appointed Eric Francois to its board of directors, effective immediately. Francois brings over 20 years of experience in healthcare and life sciences, having held leadership roles at Raymond James, Credit Suisse, SCYNEXIS, Inc., and CERo Therapeutics Holdings, Inc., and other companies, specializing in financial and strategic development. This appointment comes as the company faces financial headwinds, with shares significantly down over the past year, despite recent revenue growth and progress in its drug development and market availability.

60 Degrees Pharmaceuticals (NASDAQ: SXTP) has secured several multi-million-dollar equity financings from 2024 to 2026 to support its infectious disease pipeline. The company is actively developing tafenoquine for various new indications, including babesiosis and lung infections, while also marketing Arakoda for malaria prevention. These funding initiatives involve at-the-market offerings and registered direct offerings, enabling the expansion of clinical trials and commercialization efforts.

60 Degrees Pharmaceuticals announced that all three patients in its expanded-use clinical trial for relapsing babesiosis were cured after treatment with a tafenoquine-containing regimen. This data, combined with findings from a 2024 Yale report, suggests a near 100% cure rate for immunosuppressed babesiosis patients when weekly tafenoquine is added to existing treatments. The company believes these results warrant a review of current babesiosis treatment guidelines, despite tafenoquine not being FDA-approved for this specific condition.